Chenopodium quinoa
Chenopodium quinoa has been studied in 3 papers since 2021: 1 trial in people, 1 in animals, 1 review; 1 in the past year. It has not reached trials in people. The newest paper, Feb 4, 2026: “Quinoa Improves Glucose Metabolism and Fluctuation Based on β-Cell Function in Early-Stage Type 2 Diabetes Mellitus: A Randomized Study”.
See all 3 papers on chenopodium quinoa
At a glance
The findings reach people, from one lab or study. 1 lab in 1 country.
“reductions in postprandial blood glucose (4.57 ± 2.7 mmol/L vs 2.2 ± 2.8 mmol/L, P <0.001)”
None of its findings points the other way.
- 1 lab in 1 country
- Funder: Shandong University
- Human trial1
- Animals1
Studies in people
1 study gave chenopodium quinoa to people and measured what changed.
| What changed | Design | People | Source |
|---|---|---|---|
down: Decreases postprandial blood glucose4.57 ± 2.7 mmol/L vs 2.2 ± 2.8 mmol/L down: Decreases HbA1c0.86 ± 0.24 vs 0.28 ± 0.23 up: Increases time in range | Randomized trial14 weeks | 60 peoplebetween 20 and 70 yearsPatients with early-stage T2DM | International journal of general medicine, Feb 4, 2026 |
What did studies of chenopodium quinoa find?
4Studies of chenopodium quinoa measured 4 outcomes, among them medication reduction or withdrawal, time in range and HbA1c.
Medication reduction or withdrawal
upin humans1
1 study
Medication reduction or withdrawal
upin humans1
Chenopodium quinoa increases medication reduction or withdrawal in humans (28.6% vs 7.1%).
Human trial14 weeksn = 60
Chenopodium quinoa increases medication reduction or withdrawal in humans (early-stage T2DM) (28.6% vs 7.1%, P =0.036).
Human trialearly-stage T2DMn = 60
Time in range
upin humans1
1 study
Time in range
upin humans1
Chenopodium quinoa increases time in range in humans.
Human trial14 weeksn = 60
Chenopodium quinoa increases time in range in humans (early-stage T2DM) (94.52 ± 4.88% vs 87.83 ± 9.9%, P <0.05).
Human trialearly-stage T2DMn = 60
HbA1c
downin humans1
1 study
HbA1c
downin humans1
Chenopodium quinoa decreases HbA1c in humans (0.86 ± 0.24 vs 0.28 ± 0.23).
Human trial14 weeksn = 60
Chenopodium quinoa decreases HbA1c in humans (early-stage T2DM) (0.86 ± 0.24 vs 0.28 ± 0.23, P =0.042).
Human trialearly-stage T2DMn = 60
Postprandial blood glucose
downin humans1
1 study
Postprandial blood glucose
downin humans1
Chenopodium quinoa decreases postprandial blood glucose in humans (4.57 ± 2.7 mmol/L vs 2.2 ± 2.8 mmol/L).
Human trial14 weeksn = 60
Chenopodium quinoa decreases postprandial blood glucose in humans (early-stage T2DM) (4.57 ± 2.7 mmol/L vs 2.2 ± 2.8 mmol/L, P <0.001).
Human trialearly-stage T2DMn = 60